Header Logo

Connection

Johnny Mahlangu to Hemophilia A

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Hemophilia A.
Johnny Mahlangu
Connection Strength
28,308
Hemophilia A
  1. Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025 Mar; 31(2):214-223.
    View in: PubMed
    Score: 0,846
  2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
    View in: PubMed
    Score: 0,822
  3. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
    View in: PubMed
    Score: 0,799
  4. Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85.
    View in: PubMed
    Score: 0,794
  5. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
    View in: PubMed
    Score: 0,738
  6. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
    View in: PubMed
    Score: 0,720
  7. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239.
    View in: PubMed
    Score: 0,713
  8. Prophylaxis is the new standard of care in patients with haemophilia. S Afr Med J. 2022 05 31; 112(6):405-408.
    View in: PubMed
    Score: 0,702
  9. Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
    View in: PubMed
    Score: 0,698
  10. An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
    View in: PubMed
    Score: 0,665
  11. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
    View in: PubMed
    Score: 0,652
  12. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
    View in: PubMed
    Score: 0,640
  13. Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
    View in: PubMed
    Score: 0,611
  14. Requirements to participate in haemophilia clinical trials. Haemophilia. 2020 Apr; 26 Suppl 3:22-25.
    View in: PubMed
    Score: 0,604
  15. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,603
  16. Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. S Afr Med J. 2019 Aug 28; 109(9):639-644.
    View in: PubMed
    Score: 0,580
  17. Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761.
    View in: PubMed
    Score: 0,571
  18. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,566
  19. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,558
  20. rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
    View in: PubMed
    Score: 0,551
  21. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
    View in: PubMed
    Score: 0,551
  22. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,545
  23. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,541
  24. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May; 24 Suppl 6:15-21.
    View in: PubMed
    Score: 0,529
  25. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
    View in: PubMed
    Score: 0,491
  26. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,476
  27. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
    View in: PubMed
    Score: 0,469
  28. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
    View in: PubMed
    Score: 0,465
  29. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
    View in: PubMed
    Score: 0,456
  30. Assessment of outcomes. Haemophilia. 2014 May; 20 Suppl 4:114-20.
    View in: PubMed
    Score: 0,401
  31. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,388
  32. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
    View in: PubMed
    Score: 0,349
  33. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41.
    View in: PubMed
    Score: 0,270
  34. Guideline for the treatment of haemophilia in South Africa. S Afr Med J. 2008 Feb; 98(2 Pt 2):126-40.
    View in: PubMed
    Score: 0,260
  35. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
    View in: PubMed
    Score: 0,209
  36. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
    View in: PubMed
    Score: 0,197
  37. Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024 May; 22(5):1510-1515.
    View in: PubMed
    Score: 0,196
  38. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
    View in: PubMed
    Score: 0,195
  39. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
    View in: PubMed
    Score: 0,192
  40. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
    View in: PubMed
    Score: 0,191
  41. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
    View in: PubMed
    Score: 0,189
  42. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
    View in: PubMed
    Score: 0,188
  43. Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
    View in: PubMed
    Score: 0,186
  44. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,184
  45. World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia. 2022 09; 28(5):S129-S131.
    View in: PubMed
    Score: 0,177
  46. Haemophilia gene therapy-Update on new country initiatives. Haemophilia. 2022 May; 28 Suppl 4:61-67.
    View in: PubMed
    Score: 0,174
  47. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
    View in: PubMed
    Score: 0,173
  48. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr; 33(7-8):432-441.
    View in: PubMed
    Score: 0,173
  49. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022 05; 53:100907.
    View in: PubMed
    Score: 0,169
  50. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
    View in: PubMed
    Score: 0,168
  51. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
    View in: PubMed
    Score: 0,168
  52. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
    View in: PubMed
    Score: 0,168
  53. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
    View in: PubMed
    Score: 0,166
  54. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
    View in: PubMed
    Score: 0,164
  55. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,162
  56. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,160
  57. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
    View in: PubMed
    Score: 0,159
  58. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
    View in: PubMed
    Score: 0,159
  59. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021 01; 19 Suppl 1:21-31.
    View in: PubMed
    Score: 0,159
  60. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 11; 18(11):3074-3077.
    View in: PubMed
    Score: 0,157
  61. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
    View in: PubMed
    Score: 0,157
  62. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
    View in: PubMed
    Score: 0,155
  63. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug; 26 Suppl 6:1-158.
    View in: PubMed
    Score: 0,155
  64. The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021 03; 46:100737.
    View in: PubMed
    Score: 0,154
  65. World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 2020 Jul; 26(4):563-564.
    View in: PubMed
    Score: 0,153
  66. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,151
  67. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 2020 May; 26(3):443-449.
    View in: PubMed
    Score: 0,151
  68. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
    View in: PubMed
    Score: 0,148
  69. Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv. 2019 12 06; 3(Suppl 1):1-4.
    View in: PubMed
    Score: 0,148
  70. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,137
  71. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018 10; 16(10):2106-2110.
    View in: PubMed
    Score: 0,135
  72. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
    View in: PubMed
    Score: 0,128
  73. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,127
  74. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,125
  75. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
    View in: PubMed
    Score: 0,122
  76. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,117
  77. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
    View in: PubMed
    Score: 0,116
  78. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,116
  79. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec; 95 Suppl 81:11-21.
    View in: PubMed
    Score: 0,112
  80. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
    View in: PubMed
    Score: 0,111
  81. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
    View in: PubMed
    Score: 0,109
  82. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
    View in: PubMed
    Score: 0,107
  83. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
    View in: PubMed
    Score: 0,107
  84. Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
    View in: PubMed
    Score: 0,107
  85. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
    View in: PubMed
    Score: 0,106
  86. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
    View in: PubMed
    Score: 0,103
  87. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
    View in: PubMed
    Score: 0,102
  88. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,101
  89. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
    View in: PubMed
    Score: 0,097
  90. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47.
    View in: PubMed
    Score: 0,088
  91. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.
    View in: PubMed
    Score: 0,085
  92. Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8.
    View in: PubMed
    Score: 0,082
  93. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,068
  94. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600.
    View in: PubMed
    Score: 0,066
  95. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
    View in: PubMed
    Score: 0,033
  96. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.